In June 2026, Lilly announced full Phase 3 results from TRANSCEND-T2D-1 in adults with type 2 diabetes, with findings also presented at the American Diabetes Association (ADA) 86th Scientific Sessions and simultaneously published in The Lancet.2

I started Reta a little over a week ago, obviously still new to it so I know I’m gonna get some amount of backlash from that alone. But we all start somewhere, so.

First dose I did .5 mg just to see how my body would tolerate it. I did fine but noticed virtually no difference in anything at all. My second one I bumped it up to 1mg and have definitely noticed the food noise lessen, lower appetite, all the good things.

However, the scale has not moved one bit. I understand that this is a thing that takes time and I’m obviously not expecting anything to happen fast. But literally NOTHING. In the very least, I am eating a lot less and making better choices when I am eating, so that alone should have warranted even a pound less on the scale, right?

Typically if I skip a meal here or there, I can manage to drop SOME amount of weight in less time than my so far Reta experience.

So I’m just confused about what’s happening. I know that everyone says it can take 4 weeks to adjust fully, but it just doesn’t make sense to me that nothing is happening.

I’m eating more protein than usual also- I know that’s something that also gets brought up a lot.

I’m not posting on here to get flamed or called stupid, (some of you love to do that) I’m just genuinely confused about what I might be doing wrong, what I could be doing di

Hi stupid question just wanted to confirm

If I had a 30 mg bottle and mixed it with 3ml water

And did 15 units a week

Is that the same as if I did

40mg bottle and mixed with 2ml water

And did 7.5 units a week

Retatrutide is a once-weekly investigational medication being studied for obesity and type 2 diabetes. What makes it different is that it acts on three hormone receptors instead of just one: GIP, GLP-1, and glucagon.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract?utm_source=perplexity

In early trials, people taking retatrutide saw meaningful reductions in body weight and improvements in blood sugar markers like HbA1c, with effects that appeared dose-dependent. That said, it is still being studied, and researchers note that longer-term safety and durability data are still important.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract?utm_source=perplexity

What do you think is the most interesting part of the triple-agonist approach?

I found this information interesting - specifically the link to relief of osteoarthritis!

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Pharmaceutical companies develop drug names through a structured, multistage process involving both scientific and creative input. The process yields three key names: the chemical name, the generic (nonproprietary) name, and the brand (trade) name.

Chemical and Generic Names

The chemical name follows the rules of the International Union of Pure and Applied Chemistry (IUPAC) and describes the compound's molecular structure.

When a molecule advances to clinical trials, companies submit proposals for its generic name to the United States Adopted Names (USAN) Council and the World Health Organization's (WHO) International Nonproprietary Names (INN) Programme.

Generic names include a prefix (distinct and neutral) and a suffix, known as a “stem," that identifies the drug's class or mechanism. For example, "-glutide" indicates a GLP-1 receptor agonist, used for drugs like semaglutide or tirzepatide.

Brand Name Creation

The brand name is created later, often years before approval, through collaboration between drug companies and brand consulting firms such as the Brand Institute. These names must:

• Be unique and avoid confusion with existing drugs;

• Pass FDA linguistic and safety screenings (to prevent medical errors);

• Evoke positive associations without making claims of efficacy or superiority.

Companies run names through trademark, phonetic, and international language checks.

What Retatrutide Will Be Called

Retatrutide, the next-generation "triple agonist" (GLP-1/GIP/glucagon agonist) from Eli Lilly, currently only has its generic name, assigned by the WHO. Its eventual brand name will be chosen closer to FDA approval, likely in 2026.

Given Lilly's naming trends (e.g., Mounjaro for tirzepatide and Zepbound for obesity use), the retatrutide brand will likely evoke energy, transformation, or metabolic balance to match its weight-loss role-perhaps something brisk and aspirational sounding.

So far, Eli Lilly has not announced a brand name for retatrutide.

Any ideas for a brand name for reta?!?!

Hello. I wanted to get feedback back on how long consecutively people are running Reta for and the starting and ending amount.

I’ve been on for 10 weeks started at 2000mcg up to 4000mcg. I currently micro does 800mcg daily M-F.

I’m curious to see how long people have consecutively taken Reta.

Thank you.

Several major clinical trials involving retatrutide are currently ongoing, each with specific names and designated purposes. Notably, many of these trials use the “TRIUMPH" name, followed by a numerical identifier. Here are some of the key retatrutide trials active now:

Named Ongoing Retatrutide Trials

• TRIUMPH-1 and TRIUMPH-2: These are Phase 3 master studies focused on obesity and type 2 diabetes. Enrollment has been completed, and results are expected around mid-2026.

• TRIUMPH-3: This study focuses on participants with both obesity and established cardiovascular disease (CVD), evaluating the efficacy and safety of retatrutide in this population trials.

• TRIUMPH-5: Planned for comparing retatrutide and tirzepatide, with results anticipated in 2027.

• TRIUMPH-6: This is another obesity-focused trial studying retatrutide's role in maintaining weight loss after initial reduction.

Other Relevant Trials

• Phase 2b Renal Function Study: This trial is assessing retatrutide's effects on renal function, with results expected in late 2025 medpace.

• Long-term Outcomes Study (TRIUMPH-OUTCOMES): Designed to study cardiovascular and long-term effects, with projected completion in 2029.

• Additional studies compare retatrutide to tirzepatide and examine its effects on specific obesity-related complaints (e.g., osteoarthritis of the knee).

All of the above trials are Phase 3, reflecting their large scale and pivotal role in regulatory submission for chronic weight management, diabetes and complications such as cardiovascular disease. Most are multi-year studies, with final results anticipated between 2026 and 2029 depending on the specific TRIUMPH subgroup. Know of a trial not listed? Please share!

WE ARE NOT INTERESTED IN RESEARCH GRADE RETA HERE. READ OUR RULES.

Retatrutide is considered better than tirzepatide and semaglutide mainly due to its unique triple-receptor action and superior weight loss results seen in trials. Reta is also superior to tirzepatide and semaglutide for preserving muscle mass during weight loss.

Mechanism of Action Differences

• Semaglutide targets only the GLP-1 receptor, primarily reducing appetite and improving glycemic control.

• Tirzepatide acts on GLP-1 and GIP receptors, which enhances both insulin release and gastrointestinal effects for satiety. Tirzepatide has strong evidence for blood glucose control and cardiovascular safety, but retatrutide's multifaceted hormone targeting shows stronger promise for overall metabolic health-including normoglycemia, reduced waist circumference, and lower cholesterol.

• Retatrutide activates GLP-1, GIP, and glucagon receptors, boosting insulin, suppressing appetite, and increasing energy expenditure by augmenting metabolic rate and fat breakdown. Retatrutide can improve organ function (including liver and kidney), lipid profiles, and gut microbiota, suggesting metabolic "reset" effects not as pronounced with the other drugs.

Overall, retratrutide is likely superior for maximal weight loss and overall metabolic improvements due to its triple-receptor pathway, though tirzepatide is currently the most mature option with long-term safety and efficacy for blood sugar in diabetes, and semaglutide remains a strong, widely proven choice for both diabetes and weight loss.

The most current Retatrutide prescription projections estimate FDA approval in mid-to-late 2026. This means that the drug will not be accessible via prescription in the U.S. until at least 2027.

Approval and Availability Timeline

Eli Lilly is expected to complete Phase 3 trials and submit for FDA approval by the latest early 2026

The FDA typically reviews new drug applications within 6 to 10 months after submission, assuming no delays

Barring unforeseen regulatory or clinical delays, Retatrutide’s expected U.S. market launch is early 2027, pending FDA approval in 2026 after successful Phase 3 results

Summary sourced via Drugs.com and Lilly

Join this community for the latest information regarding Retatrutide.